Assessing Second‐Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene‐Driven Stage IV Non‐Small Cell Lung Cancer, Following a First‐Line EGFR‐TKI Therapy. This evidence concerns the gene EGFR and lung cancer.